CSR Press Release

March 5, 2007- Novo Nordisk, the Danish-based healthcare company, has published its 2006 Annual Report, backed by an online version (available via www.reportalert.info/ra/NovoNord050307.htm), with additional background, context and detail. The printed report comes in two sections, with 50 pages of management report and feature articles; and the consolidated financial and non-financial statements. The report complies with the IFRS and is in accordance with the GRI. It has been independently audited and assured.

For the third year, Novo Nordisk issues an integrated report, combining both financial and non-financial information in one publication to enhance stakeholders’ valuation of the company. With an emphasis on shareholders, the annual reports seek to provide these with insights into the company’s strategies, activities and achievements.

The report accounts for the company’s performance during the year and discusses key challenges. It presents strategic initiatives to developing the business in order to meet its targets and sustain long-term shareholder value creation. And it explains Novo Nordisk’s way of doing business as a values-based company guided by a vision.

As a focused healthcare company, Novo Nordisk is committed to leading the fight against diabetes. This year’s report includes feature articles on the company’s changing diabetes campaign including the active support for a UN Resolution on Diabetes. Other featured sustainability programmes address global access to health, climate change, business ethics and responsible sourcing.

Hard copies in English or Danish can be ordered from the download centre via http://www.reportalert.info/ra/NovoNord050307.htm. Novo Nordisk values stakeholders’ review of the company’s reporting and welcomes any questions or comments. Please send emails to the company contact available on http://www.reportalert.info/ra/NovoNord050307.htm. Feedback on this report can be left via CorporateRegister.com here http://www.corporateregister.com/search/report.cgi?com=0&num=17728

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within haemostasis management, growth hormone therapy and hormone replacement therapy. With headquarters in Denmark, Novo Nordisk employs approximately 23,000 full-time employees in 79 countries.

Visit www.CorporateRegister.com to access 13,400 CSR reports.

For more information, please contact: